Evolution of amoxicillin/clavulanate in the treatment of adults with acute bacterial rhinosinusitis and community-acquired pneumonia in response to antimicrobial-resistance patterns

Clinics in Laboratory Medicine

Volumn 24, Issue 2, 2004, Pages 531-551

  File Jr , Thomas M ^a,b,f   Benninger, Michael S ^c   Jacobs, Michael R ^d,e  

^a NORTHEAST OHIO MEDICAL UNIVERSITY   (United States)

^b SUMMA HEALTH SYSTEM   (United States)

^c HENRY FORD HOSPITAL   (United States)

^d CASE WESTERN RESERVE UNIVERSITY   (United States)

^e UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^f Infectious Disease Service   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIINFECTIVE AGENT; AZITHROMYCIN; BETA LACTAM; BETA LACTAMASE INHIBITOR; CEFACLOR; CEFIXIME; CEFPODOXIME; CEFPROZIL; CEFTRIAXONE; CEFUROXIME; CEFUROXIME AXETIL; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; CLARITHROMYCIN; CLAVULANIC ACID; CLINDAMYCIN; COTRIMOXAZOLE; DOXYCYCLINE; ERYTHROMYCIN; GATIFLOXACIN; GEMIFLOXACIN; LEVOFLOXACIN; LORACARBEF; MOXIFLOXACIN; QUINOLONE DERIVATIVE; TETRACYCLINE DERIVATIVE; UNINDEXED DRUG;

ANTIBIOTIC RESISTANCE; BACTERIAL INFECTION; BACTERIAL PNEUMONIA; BACTERIAL STRAIN; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; CROSS RESISTANCE; DRUG EFFICACY; DRUG MECHANISM; DRUG RELEASE; DRUG TOLERABILITY; HAEMOPHILUS INFLUENZAE; HEALTH CARE SYSTEM; HUMAN; INFECTION RISK; MORAXELLA CATARRHALIS; POPULATION; PREVALENCE; PRIORITY JOURNAL; REVIEW; RHINOSINUSITIS; TREATMENT OUTCOME;

AMOXICILLIN-POTASSIUM CLAVULANATE COMBINATION; ANTI-BACTERIAL AGENTS; BACTERIA; COMMUNITY-ACQUIRED INFECTIONS; DRUG RESISTANCE, BACTERIAL; DRUG THERAPY, COMBINATION; HUMANS; MICROBIAL SENSITIVITY TESTS; PNEUMONIA; SINUSITIS;

EID: 2942596229     PISSN: 02722712     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cll.2004.03.003     Document Type: Review

References (59)

1. Niederman M.S., Mandell L.A., Anzueto A., et al. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med. 163:(7):2001;1730-1754
2. Anon J.B., Jacobs M.R., Poole M.D., et al. Antimicrobial treatment guidelines for acute bacterial rhinosinusitis. Otolaryngol Head Neck Surg. 130:(1 Suppl):2004;1-45
3. Ray N.F., Baraniuk J.N., Thamer M., et al. Healthcare expenditures for sinusitis in 1996: contributions of asthma, rhinitis, and other airway disorders. J Allergy Clin Immunol. 103:(3 Pt 1):1999;408-414
4. McCaig L.F., Hughes J.M. Trends in antimicrobial drug prescribing among office-based physicians in the United States. JAMA. 273:(3):1995;214-219
5. Scott Levin Prescription Audit from Verispan. LLC. January-December 2002.
6. Antimicrobial treatment guidelines for acute bacterial rhinosinusitis. Sinus and Allergy Health Partnership. Otolaryngol Head Neck Surg. 123:(1 Pt 2):2000;5-31
7. Bartlett J.G., Dowell S.F., Mandell L.A., File T.M. Jr., Musher D.M., Fine M.J. Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America. Clin Infect Dis. 31:(2):2000;347-382
8. Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 46:(RR-8):1997;1-24
9. Fine M.J., Smith M.A., Carson C.A., et al. Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis. JAMA. 275:(2):1996;134-141
10. Gotfried M.H. Epidemiology of clinically diagnosed community-acquired pneumonia in the primary care setting: results from the 1999-2000 respiratory surveillance program. Am J Med. 111:(Suppl 9A):2001;25S-29S. [discussion 36S-8S]
11. Jacobs M.R. Emergence of antibiotic resistance in upper and lower respiratory tract infections. Am J Manag Care. 5:(11 Suppl):1999;S651-S661
12. Appelbaum P.C., Bhamjee A., Scragg J.N., Hallett A.F., Bowen A.J., Cooper R.C. Streptococcus pneumoniae resistant to penicillin and chloramphenicol. Lancet. 2:(8046):1977;995-997
13. GlaxoSmithKline. Antibiotic treatment and resistance timeline. Available at: http://www.augmentin.com. Accessed August 2, 2002.
14. Jacobs M.R., Koornhof H.J., Robins-Browne R.M., et al. Emergence of multiply resistant pneumococci. N Engl J Med. 299:(14):1978;735-740
15. Naraqi S., Kirkpatrick G.P., Kabins S. Relapsing pneumococcal meningitis: isolation of an organism with decreased susceptibility to penicillin. G. J Pediatr. 85:(5):1974;671-673
16. Doern G.V., Heilmann K.P., Huynh H.K., Rhomberg P.R., Coffman S.L., Brueggemann A.B. Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999-2000, including a comparison of resistance rates since 1994-1995. Antimicrob Agents Chemother. 45:(6):2001;1721-1729
17. Doern G.V., Brueggemann A.B., Huynh H., Wingert E. Antimicrobial resistance with Streptococcus pneumoniae in the United States, 1997-98. Emerg Infect Dis. 5:(6):1999;757-765
18. Doern G.V., Brueggemann A., Holley H.P. Jr., Rauch A.M. Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients in the United States during the winter months of 1994 to 1995: results of a 30-center national surveillance study. Antimicrob Agents Chemother. 40:(5):1996;1208-1213
19. Spika J.S., Facklam R.R., Plikaytis B.D., Oxtoby M.J. Antimicrobial resistance of Streptococcus pneumoniae in the United States, 1979-1987. The Pneumococcal Surveillance Working Group. J Infect Dis. 163:(6):1991;1273-1278
20. Thornsberry C., Sahm D.F., Kelly L.J., et al. Regional trends in antimicrobial resistance among clinical isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States: results from the TRUST Surveillance Program, 1999-2000. Clin Infect Dis. 34:(Suppl 1):2002;S4-S16
21. Jacobs M.R., Felmingham D., Appelbaum P.C., Gruneberg R.N. The Alexander Project 1998-2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents. J Antimicrob Chemother. 52:(2):2003;229-246
22. Chambers H.F. Penicillin-binding protein-mediated resistance in pneumococci and staphylococci. J Infect Dis. 179:(Suppl 2):1999;S353-S359
23. Bush K. Beta-lactamase inhibitors from laboratory to clinic. Clin Microbiol Rev. 1:(1):1988;109-123
24. Medeiros A.A. Evolution and dissemination of beta-lactamases accelerated by generations of beta-lactam antibiotics. Clin Infect Dis. 24:(Suppl 1):1997;S19-S45
25. Jacobs M.R. Drug-resistant Streptococcus pneumoniae: rational antibiotic choices. Am J Med. 106:(5A):1999;19S-25S. [discussion 48S-52S]
26. Khan W., Ross S., Rodriguez W., Controni G., Saz A.K. Haemophilus influenzae type B resistant to ampicillin. A report of two cases. JAMA. 229:(3):1974;298-301
27. Jorgensen J.H., Doern G.V., Maher L.A., Howell A.W., Redding J.S. Antimicrobial resistance among respiratory isolates of Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae in the United States. Antimicrob Agents Chemother. 34:(11):1990;2075-2080
28. Doern G.V., Brueggemann A.B., Pierce G., Holley H.P. Jr., Rauch A. Antibiotic resistance among clinical isolates of Haemophilus influenzae in the United States in 1994 and 1995 and detection of beta-lactamase-positive strains resistant to amoxicillin-clavulanate: results of a national multicenter surveillance study. Antimicrob Agents Chemother. 41:(2):1997;292-297
29. Jones M.E., Karlowsky J.A., Blosser-Middleton R., Critchley I.A., Thornsberry C., Sahm D.F. Apparent plateau in beta-lactamase production among clinical isolates of Haemophilus influenzae and Moraxella catarrhalis in the United States: results from the LIBRA Surveillance initiative. Int J Antimicrob Agents. 19:(2):2002;119-123
30. Thornsberry C., Ogilvie P.T., Holley H.P. Jr., Sahm D.F. Survey of susceptibilities of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis isolates to 26 antimicrobial agents: a prospective US study. Antimicrob Agents Chemother. 43:(11):1999;2612-2623
31. Doern G.V., Jones R.N., Pfaller M.A., Kugler K. Haemophilus influenzae and Moraxellacatarrhalis from patients with community-acquired respiratory tract infections: antimicrobial susceptibility patterns from the SENTRY antimicrobial Surveillance Program (United States and Canada, 1997). Antimicrob Agents Chemother. 43:(2):1999;385-389
32. Hakenbeck R., Kaminski K., Konig A., et al. Penicillin-binding proteins in beta-lactam-resistant streptococcus pneumoniae. Microb Drug Resist. 5:(2):1999;91-99
33. Craig W.A. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis. 26:(1):1998;1-10. [quiz 11-2]
34. Chen D.K., McGeer A., de Azavedo J.C., Low D.E. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network. N Engl J Med. 341:(4):1999;233-239
35. Ho P.L., Yung R.W., Tsang D.N., et al. Increasing resistance of Streptococcus pneumoniae to fluoroquinolones: results of a Hong Kong multicentre study in 2000. J Antimicrob Chemother. 48:(5):2001;659-665
36. Hyde T.B., Gay K., Stephens D.S., et al. Macrolide resistance among invasive Streptococcus pneumoniae isolates. JAMA. 286:(15):2001;1857-1862
37. Pihlajamaki M., Kotilainen P., Kaurila T., Klaukka T., Palva E., Huovinen P. Macrolide-resistant Streptococcus pneumoniae and use of antimicrobial agents. Clin Infect Dis. 33:(4):2001;483-488
38. Appelbaum P.C. Resistance among Streptococcus pneumoniae: implications for drug selection. Clin Infect Dis. 34:(12):2002;1613-1620
39. Hofmann J., Cetron M.S., Farley M.M., et al. The prevalence of drug-resistant Streptococcus pneumoniae in Atlanta. N Engl J Med. 333:(8):1995;481-486
40. Fogarty C., Goldschmidt R., Bush K. Bacteremic pneumonia due to multidrug-resistant pneumococci in 3 patients treated unsuccessfully with azithromycin and successfully with levofloxacin. Clin Infect Dis. 31:(2):2000;613-615
41. Kelley M.A., Weber D.J., Gilligan P., Cohen M.S. Breakthrough pneumococcal bacteremia in patients being treated with azithromycin and clarithromycin. Clin Infect Dis. 31:(4):2000;1008-1011
42. Lonks J.R., Garau J., Gomez L., et al. Failure of macrolide antibiotic treatment in patients with bacteremia due to erythromycin-resistant Streptococcus pneumoniae. Clin Infect Dis. 35:(5):2002;556-564
43. Musher D.M., Dowell M.E., Shortridge V.D., et al. Emergence of macrolide resistance during treatment of pneumococcal pneumonia. N Engl J Med. 346:(8):2002;630-631
44. Reid R. Jr., Bradley J.S., Hindler J. Pneumococcal meningitis during therapy of otitis media with clarithromycin. Pediatr Infect Dis J. 14:(12):1995;1104-1105
45. Waterer G.W., Wunderink R.G., Jones C.B. Fatal pneumococcal pneumonia attributed to macrolide resistance and azithromycin monotherapy. Chest. 118:(6):2000;1839-1840
46. Heffelfinger J.D., Dowell S.F., Jorgensen J.H., et al. Management of community-acquired pneumonia in the era of pneumococcal resistance: a report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group. Arch Intern Med. 160:(10):2000;1399-1408
47. Mandell L.A., Bartlett J.G., Dowell S.F., File T.M. Jr., Musher D.M., Whitney C. Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin Infect Dis. 37:(11):2003;1405-1433
48. Fine M.J., Auble T.E., Yealy D.M., et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med. 336:(4):1997;243-250
49. Nicholson SC, Conetta BJ, Mayer HB. Difference in pathogens isolated from outpatients and inpatients with community-acquired pneumonia. Presented at the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Ontario, Canada, September 17-20, 2000.
50. Donowitz G.R., Brandon M.L., Salisbury J.P., et al. Sparfloxacin versus cefaclor in the treatment of patients with community-acquired pneumonia: a randomized, double-masked, comparative, multicenter study. Clin Ther. 19:(5):1997;936-953
51. Lode H., Garau J., Grassi C., et al. Treatment of community-acquired pneumonia: a randomized comparison of sparfloxacin, amoxycillin-clavulanic acid and erythromycin. Eur Respir J. 8:(12):1995;1999-2007
52. Mundy L.M., Oldach D., Auwaerter P.G., et al. Implications for macrolide treatment in community-acquired pneumonia. Hopkins CAP Team. Chest. 113:(5):1998;1201-1206
53. File T.M. Jr., Tan J.S., Plouffe J.F. The role of atypical pathogens: Mycoplasma pneumoniae, Chlamydia pneumoniae, and Legionella pneumophila in respiratory infection. Infect Dis Clin North Am. 12:(3):Sep 1998;569-592. [vii.]
54. Kaye C.M., Allen A., Perry S., et al. The clinical pharmacokinetics of a new pharmacokinetically enhanced formulation of amoxicillin/clavulanate. Clin Ther. 23:(4):2001;578-584
55. Augmentin XR prescribing information. Research Triangle Park. 2002;GlaxoSmithKline, NC
56. File T.M. Jr., Jacobs M.R., Poole M.D., Wynne B. Outcome of treatment of respiratory tract infections due to Streptococcus pneumoniae, including drug-resistant strains, with pharmacokinetically enhanced amoxycillin/ clavulanate. Int J Antimicrob Agents. 20:(4):2002;235-247
57. File T, Lode H, Kurz H, Crann R and the 600 Study Group. Comparative efficacy/safety of pharmacokinetically enhanced amoxicillin/clavulanate 200/125 mg vs amoxicillin/clavulanate 875/125 mg in community-acquired pneumonia (CAP). Presented at the 99th International Conference of the American Thoracic Society. Seattle, Washington, May 16-21, 2003.
58. Petitpretz P., Chidiac C., Soriano F., Garau J., Stevenson K., Rouffiac E. The efficacy and safety of oral pharmacokinetically enhanced amoxycillin-clavulanate 2000/125 mg, twice daily, versus oral amoxycillin-clavulanate 1000/125 mg, three times daily, for the treatment of bacterial community-acquired pneumonia in adults. Int J Antimicrob Agents Aug. 20:(2):Aug 2002;119-129
59. Garau J, Twynholm M, Garcia-Mendez E. and the 557 study group. Comparative efficacy and safety of pharmacokinetically enhanced amoxicillin/clavulanate 2000/125 mg b.d. versus amoxicillin/clavulanate 875/125 mg t.d.s. in community-acquired pneumonia (CAP) [poster]. Presented at the 12th European Congress of Clinical Microbiology and Infectious Diseases. Milan, Italy, April 24-27, 2002.